JP2017507994A - チアクマイシンｂの新たな多形及び新たな固体状態 - Google Patents

チアクマイシンｂの新たな多形及び新たな固体状態 Download PDF

Info

Publication number
JP2017507994A
JP2017507994A JP2016558001A JP2016558001A JP2017507994A JP 2017507994 A JP2017507994 A JP 2017507994A JP 2016558001 A JP2016558001 A JP 2016558001A JP 2016558001 A JP2016558001 A JP 2016558001A JP 2017507994 A JP2017507994 A JP 2017507994A
Authority
JP
Japan
Prior art keywords
solvate
thiacomycin
crystal
crystals
xrpd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016558001A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017507994A5 (ja
Inventor
クルーゲ、シュテファン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xellia Pharmaceuticals ApS
Original Assignee
Xellia Pharmaceuticals ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xellia Pharmaceuticals ApS filed Critical Xellia Pharmaceuticals ApS
Publication of JP2017507994A publication Critical patent/JP2017507994A/ja
Publication of JP2017507994A5 publication Critical patent/JP2017507994A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
JP2016558001A 2014-03-18 2015-03-17 チアクマイシンｂの新たな多形及び新たな固体状態 Pending JP2017507994A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461954715P 2014-03-18 2014-03-18
US61/954,715 2014-03-18
US201462020570P 2014-07-03 2014-07-03
US62/020,570 2014-07-03
PCT/EP2015/055531 WO2015140153A1 (en) 2014-03-18 2015-03-17 New polymorphs and new solid states of tiacumicin b

Publications (2)

Publication Number Publication Date
JP2017507994A true JP2017507994A (ja) 2017-03-23
JP2017507994A5 JP2017507994A5 (ja) 2018-04-12

Family

ID=52697399

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016558001A Pending JP2017507994A (ja) 2014-03-18 2015-03-17 チアクマイシンｂの新たな多形及び新たな固体状態

Country Status (17)

Country Link
US (1) US10227371B2 (pt-PT)
EP (1) EP3119793B1 (pt-PT)
JP (1) JP2017507994A (pt-PT)
KR (1) KR20160134719A (pt-PT)
CN (1) CN106103462A (pt-PT)
AU (1) AU2015233583B2 (pt-PT)
BR (1) BR112016021542B1 (pt-PT)
CA (1) CA2940902C (pt-PT)
DK (1) DK3119793T3 (pt-PT)
ES (1) ES2668351T3 (pt-PT)
HR (1) HRP20180668T1 (pt-PT)
HU (1) HUE038426T2 (pt-PT)
IL (2) IL247726A0 (pt-PT)
PL (1) PL3119793T3 (pt-PT)
PT (1) PT3119793T (pt-PT)
SI (1) SI3119793T1 (pt-PT)
WO (1) WO2015140153A1 (pt-PT)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108727387B (zh) * 2018-07-25 2021-03-16 天津大学 依鲁替尼乙酸异丙酯溶剂化合物及其制备方法
CN109053738B (zh) * 2018-08-29 2020-10-16 浙江工业大学 一种依鲁替尼的溶剂化物及其制备方法
CN114224899B (zh) * 2020-09-09 2024-04-26 首都医科大学附属北京胸科医院 非达霉素用于制备抑制脓肿分枝杆菌活性的产品

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008528582A (ja) * 2005-01-31 2008-07-31 オプティマー ファーマシューティカルズ、インコーポレイテッド １８員大環状化合物及びその類似化合物
JP2010516681A (ja) * 2007-01-22 2010-05-20 オプティマー ファーマシューティカルズ、インコーポレイテッド 大環状多形、そのような多形を含む組成物、ならびにその使用方法および製造方法
US20130267692A1 (en) * 2012-04-05 2013-10-10 Olon S.P.A. Procedure for the purification of tiacumicin b
WO2013170142A1 (en) * 2012-05-10 2013-11-14 Teva Pharmaceutical Works Ltd. Solid state forms of fidaxomycin and processes for preparation thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4918174A (en) 1986-09-26 1990-04-17 Abbott Laboratories Tiacumicin compounds
WO2004014295A2 (en) 2002-07-29 2004-02-19 Optimer Pharmaceuticals, Inc. Tiacumicin production
ZA200905337B (en) 2007-01-22 2010-10-27 Optimer Pharmaceuticals Inc Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
US8722863B2 (en) 2012-05-10 2014-05-13 Teva Pharmaceutical Works Ltd. Solid state forms of fidaxomycin and processes for preparation thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008528582A (ja) * 2005-01-31 2008-07-31 オプティマー ファーマシューティカルズ、インコーポレイテッド １８員大環状化合物及びその類似化合物
JP2010516681A (ja) * 2007-01-22 2010-05-20 オプティマー ファーマシューティカルズ、インコーポレイテッド 大環状多形、そのような多形を含む組成物、ならびにその使用方法および製造方法
US20130267692A1 (en) * 2012-04-05 2013-10-10 Olon S.P.A. Procedure for the purification of tiacumicin b
WO2013170142A1 (en) * 2012-05-10 2013-11-14 Teva Pharmaceutical Works Ltd. Solid state forms of fidaxomycin and processes for preparation thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
松岡 正邦, 結晶多形の基礎と応用, vol. 普及版 第１刷, JPN7017001304, 22 October 2010 (2010-10-22), pages 105 - 117, ISSN: 0003848100 *
芦澤 一英、他, 医薬品の多形現象と晶析の科学, JPN7016001492, 20 September 2002 (2002-09-20), pages 272 - 317, ISSN: 0003848099 *

Also Published As

Publication number Publication date
US10227371B2 (en) 2019-03-12
IL265180B (en) 2022-01-01
PT3119793T (pt) 2018-05-10
AU2015233583B2 (en) 2019-04-11
IL247726A0 (en) 2016-11-30
DK3119793T3 (en) 2018-05-22
IL265180A (en) 2019-05-30
AU2015233583A1 (en) 2016-09-15
WO2015140153A1 (en) 2015-09-24
ES2668351T3 (es) 2018-05-17
BR112016021542A2 (pt-PT) 2017-08-15
CN106103462A (zh) 2016-11-09
SI3119793T1 (en) 2018-06-29
CA2940902C (en) 2022-10-25
US20170081355A1 (en) 2017-03-23
EP3119793B1 (en) 2018-03-14
PL3119793T3 (pl) 2018-07-31
HRP20180668T1 (hr) 2018-06-15
CA2940902A1 (en) 2015-09-24
HUE038426T2 (hu) 2018-10-29
KR20160134719A (ko) 2016-11-23
BR112016021542B1 (pt) 2023-01-31
EP3119793A1 (en) 2017-01-25

Similar Documents

Publication Publication Date Title
IL265180A (en) New polymorphs and new solid states of thiacomycin b
GB2558514A (en) Process for the synthesis of stable amorphous ibrutinib
JP3317972B2 (ja) 結晶性ｎ−アセチルノイラミン酸誘導体およびその製造法
WO2018196860A1 (zh) 羧酸铵盐化合物、其晶型、无定形物及其制备方法
EP4313945B1 (en) Crystalline hydrobromide salt of 5-meo-dmt
US10981955B2 (en) Method of manufacturing a pharmaceutical composition
CA2980224C (en) Crystalline form of ahu377, preparation method and use thereof
US20150141673A1 (en) Novel crystalline for w of cabazitaxel and method for preparing it
Sohrab et al. Pharmaceutical Co-crystal: A New Paradigm for Enhancing the Physicochemical Properties of Active Pharmaceutical Ingredient.
US20080319197A1 (en) Crystalline Form of Remifentanil Hydrochloride
EP3710425A1 (en) Solid state forms of elafibranor
EP3397626A1 (en) Crystal forms of immunomodulatory drug pomalidomide and co-crystal with gentisic acid
JP2006328055A (ja) ２’−（４’−エチルベンジル）フェニル５−チオ−β−Ｄ−グルコピラノシドのＡ型結晶及びその製造方法
TWI707851B (zh) 哌嗪化合物的新穎結晶
JP2015166331A (ja) ナルフラフィンの結晶およびその製造方法
WO2018209667A1 (zh) 多环杂环化合物的晶型、其制备方法、应用及组合物
Hilfiker The Importance of Choosing the Optimal Solid Form of a Drug
BR102015004857B1 (pt) Processo para a preparação de imatinibe e mesilato de imatinibe forma alfa-2 não-agulha
BR102014014018A2 (pt) processo para a preparação de imatinibe e mesilato de imatinibe forma alfa-2 não-agulha
BRPI0708991A2 (pt) polimorfos de docetaxel e processos
TW201521791A (zh) ５－｛８－［（３ｒ）－４－乙醯基－３－甲基哌－１－基］－６－□啉－４－基－９－（２，２，２－三氟乙基）－９ｈ－嘌呤－２－基｝嘧啶－２－胺、及其藥理容許鹽之新穎結晶、及其製造方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180302

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20180302

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20180320

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180627

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180801